

Supporting Information

Evaluation of cationic assemblies constructed with amino-acid based lipids for plasmid DNA delivery

Yosuke Obata, Daisuke Suzuki, and Shinji Takeoka

Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, Tokyo 169-8555, Japan.

y-obata@asagi.waseda.jp

List of contents:	Page
Synthesis of lipids a-c	3
Figure S1. ¹ H-NMR spectrum and characterization of compound a	3-4
Figure S2. ¹ H-NMR spectrum and characterization of compound b	4
Figure S3. ¹ H-NMR spectrum and characterization of compound c	5
Synthesis of lipids 1a-1c , 2a-2c , and 3a-3c .	6
Figure S4. ¹ H-NMR spectrum and characterization of compound 1a	7
Figure S5. ¹ H-NMR spectrum and characterization of compound 1b	8
Figure S6. ¹ H-NMR spectrum and characterization of compound 1c	9
Figure S7. ¹ H-NMR spectrum and characterization of compound 2a	10
Figure S8. ¹ H-NMR spectrum and characterization of compound 2b	11
Figure S9. ¹ H-NMR spectrum and characterization of compound 2c	12

Figure S10. ^1H -NMR spectrum and characterization of compound 3a	13
Figure S11. ^1H -NMR spectrum and characterization of compound 3b	14
Figure S12. ^1H -NMR spectrum and characterization of compound 3c	15

Synthesis of the hydrophobic moiety of cationic lipids. a (1,5-ditetradecyl-L-glutamate), **b** (1,5-dihexadecyl-L-glutamate), and **c** (1,5-dioctadecyl-L-glutamate) were synthesized as shown in Scheme. L-Glutamic acid (1 g, 6.8 mmol) and *p*-Tos (1.65 g, 8.16 mmol) were dissolved in benzene (200 mL) and refluxed for 1 hr at 90°C. Tetradecylalcohol, hexadecylalcohol or octadecylalcohol (15 mmol) was added to the solution, followed by stirring for 12 hr under reflux. The reaction mixture was evaporated and then dissolved in chloroform (100 ml). The chloroform solution was treated with a sodium carbonate solution (100 ml x 2) and washed with distilled water (100 ml x 1). After the chloroform solution was evaporated, **a**, **b** and **c** were recrystallized from methanol (100 mL) at 4°C to obtain a white powder with a yield of 76%, 82% and 83 %, respectively.




Figure 1S. ¹H-NMR spectrum of 1,5-ditetradecyl-L-glutamate (**a**).

1,5-Ditetradecyl-L-glutamate (a): R_f 0.75 (CHCl_3 :MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.28 (m, 44H, CH_2 (myristoyl)), 1.58-1.66 (m, 4H, $\text{COOCH}_2\text{CH}_2$); 2.01-2.10 (m, 2H, NH_2CHCH_2), 2.45 (t, 2H, CH_2CO); 3.80 (t, 1H, NH_2CH), 4.06-4.14 (t, 4H, COOCH_2), 7.18, 7.73 (d, 2H, NH_2). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{33}\text{H}_{65}\text{NO}_4$, 539.87; found, 540.5.




Figure 2S. $^1\text{H-NMR}$ spectrum of 1,5-dihexadecyl-L-glutamate (b).

1,5-Dihexadecyl-L-glutamate (b): R_f 0.73 (CHCl_3 :MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 52H, CH_2 (palmitoyl)), 1.55-1.64 (m, 4H, $\text{COOCH}_2\text{CH}_2$); 2.21 (m, 2H, NH_2CHCH_2), 2.51 (t, 2H, CH_2CO), 4.04 (t, 1H, NH_2CH), 4.10-4.14 (t, 4H, COOCH_2), 7.18, 7.72 (d, 2H, NH_2). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{37}\text{H}_{73}\text{NO}_4$, 595.58; found, 595.5.




Figure 3S. $^1\text{H-NMR}$ spectrum of 1,5-dihexadecyl-L-glutamate (c).

1,5-Dihexadecyl-L-glutamate (c): R_f 0.75 (CHCl_3 : MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 : MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 60H, CH_2 (stearyl)), 1.52-1.67 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 1.90-2.12 (m, 2H, NH_2CHCH_2), 2.47 (t, 2H, CH_2CO), 3.59 (t, 1H, NH_2CH), 4.06-4.15 (t, 4H, COOCH_2), 7.18, 7.73 (d, 2H, NH_2). MS(ESI): $(\text{M}+\text{H})^+$ calcd for $\text{C}_{33}\text{H}_{65}\text{NO}_4$, 652.09; found, 652.5.

Syntheses of amino-acid based cationic lipids. Amino acid-based cationic lipids having a cationic head-group were synthesized as shown in Scheme. **a**, **b** or **c** (1.68 mmol) and triethylamine (2 mmol) were dissolved in dichloromethane and stirred for 1 hr at room temperature. Either Boc-Lys(Boc)-OSu, Boc-His(1-Boc)-OSu, or Boc-Arg(Boc)₂-OH was added to the solution and stirred for 6 hr at room temperature. The reaction mixture was evaporated and then dissolved in chloroform (100 ml). The chloroform solution was treated with a sodium carbonate solution (100 ml x 2) and washed with distilled water (100 ml x 1). After the chloroform solution was evaporated, the amino group-protected intermediates were recrystallized from methanol (50 mL) at 4°C. After deprotection with trifluoroacetic acid (20 mL) for 2 hr at 4°C, **1a** (1,5-ditetradecyl *N*-lysyl-L-glutamate), **1b** (1,5-dihexadecyl *N*-lysyl-L-glutamate) or **1c** (1,5-dioctadecyl *N*-lysyl-L-glutamate) were obtained as a white powder (yields: 61%, 90%, or 86%, respectively) after freeze-drying with benzene. Using a similar method to that described above, **2a** (1,5-ditetradecyl *N*-histidyl-L-glutamate), **2b** (1,5-dihexadecyl *N*-histidyl-L-glutamate) and **2c** (1,5-dioctadecyl *N*-histidyl-L-glutamate) were obtained with a yield of 68%, 81% and 80%, respectively. For the synthesis of arginine-type lipids, BOP reagent was used for the amide linkage. Compounds **3a** (1,5-ditetradecyl *N*-arginyl-L-glutamate), **3b** (1,5-dihexadecyl *N*-arginyl-L-glutamate) and **3c** (1,5-dioctadecyl *N*-arginyl-L-glutamate) were obtained with a yield of 40%, 55% and 70%, respectively.

1a: 1,5-Ditetradecyl *N*-lysyl-L-glutamate




Figure 4S. $^1\text{H-NMR}$ spectrum of 1,5-ditetradecyl *N*-lysyl-L-glutamate (**1a**).

1,5-Ditetradecyl *N*-lysyl-L-glutamate (1a): R_f 0.14 (CHCl_3 :MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 44H, CH_2 (myristoyl)), 1.53 (m, 2H, $\text{NH}_2\text{CHCH}_2\text{CH}_2$), 1.62 (m, 4H, COOCH_2), 1.72 (m, 2H, $\text{NH}_2\text{CH}_2\text{CH}_2$), 1.80-1.95 (m, 2H, NH_2CHCH_2), 1.96-2.25 (m, 2H, NHCHCH_2), 2.43 (m, 2H, CH_2COO), 2.96 (m, 2H, NH_2CH_2), 3.97 (m, 1H, NH_2CHCO), 4.00-4.20 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 4.51 (q, 1H, NHCH). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{39}\text{H}_{77}\text{N}_3\text{O}_5$, 668.05; found, 669.7.

1b: 1,5-Dihexadecyl *N*-lysyl-L-glutamate




Figure 5S. $^1\text{H-NMR}$ spectrum of 1,5-dihexadecyl *N*-lysyl-L-glutamate (**1b**).

1,5-Dihexadecyl *N*-lysyl-L-glutamate (1b**):** R_f 0.19 (CHCl_3 :MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 52H, CH_2 (palmitoyl)), 1.56 (m, 2H, $\text{NH}_2\text{CHCH}_2\text{CH}_2$), 1.62 (m, 4H, COOCH_2), 1.69 (m, 2H, $\text{NH}_2\text{CH}_2\text{CH}_2$), 1.87 (m, 2H, NH_2CHCH_2), 1.94-2.25 (m, 2H, NHCHCH_2), 2.43 (m, 2H, CH_2COO), 2.95 (m, 2H, NH_2CH_2), 3.97 (m, 1H, NH_2CHCO), 4.02-4.16 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 4.51 (q, 1H, NHCH). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{43}\text{H}_{85}\text{N}_3\text{O}_5$, 724.15; found, 724.7.




Figure 6S. ¹H-NMR spectrum of 1,5-dioctadecyl *N*-lysyl-L-glutamate (**1c**).

1,5-Dioctadecyl *N*-lysyl-L-glutamate (1c): *R_f* 0.06 (CHCl₃:MeOH 4:1). ¹H-NMR (CDCl₃:MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH₂CH₃); 1.26 (m, 60H, CH₂(stearyl)), 1.52 (m, 2H, NH₂CHCH₂CH₂), 1.64 (m, 4H, COOCH₂CH₂), 1.72 (m, 2H, NH₂CH₂CH₂), 1.88 (m, 2H, NH₂CHCH₂), 1.95-2.27 (m, 2H, NHCHCH₂), 2.44 (m, 2H, CH₂COO), 2.94 (m, 2H, NH₂CH₂), 3.94 (m, 1H, NH₂CHCO), 4.05-4.12 (m, 4H, COOCH₂CH₂), 4.52 (q, 1H, NHCH). MS(ESI): (M+H)⁺ calcd. for C₄₃H₈₅N₃O₅, 780.26; found, 780.7.




Figure 7S. ¹H-NMR spectrum of 1,5-ditetradecyl *N*-histidyl-L-glutamate (**2a**).

1,5-Ditetradecyl *N*-histidyl-L-glutamate (2a): R_f 0.14 (CHCl₃:MeOH 4:1). ¹H-NMR (CDCl₃:MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH₂CH₃); 1.26 (m, 44H, CH₂(myristoyl)), 1.64 (m, 4H, COOCH₂CH₂), 1.96-2.25 (m, 2H, NHCHCH₂), 2.40 (t, 2H, NHCHCH₂CH₂), 2.94-3.19 (q, 2H, NH₂CHCH₂), 3.93 (q, 1H, NHCH), 4.05-4.16 (m, 4H, COOCH₂), 4.52 (q, 1H, NH₂CH), 7.00 (s, 1H, CH₂C=CH), 7.82 (s, 1H, N=CH). MS(ESI): (M+H)⁺ calcd. for C₃₉H₇₂N₄O₅, 677.01; found, 677.6.




Figure 8S. $^1\text{H-NMR}$ spectrum of 1,5-dihexadecyl *N*-histidyl-L-glutamate (**2b**).

1,5-Dihexadecyl *N*-histidyl-L-glutamate (2b**):** R_f 0.15 (CHCl_3 :MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 52H, CH_2 (palmitoyl)), 1.64 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 1.96-2.29 (m, 2H, NHCHCH_2), 2.46 (t, 2H, $\text{NHCHCH}_2\text{CH}_2$), 3.20-3.49 (q, 2H, NH_2CHCH_2), 4.05-4.14 (m, 4H, COOCH_2), 4.33 (q, 1H, NHCH), 4.52 (q, 1H, NH_2CH), 7.82 (s, 1H, $\text{N}=\text{CH}$). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{43}\text{H}_{80}\text{N}_4\text{O}_5$, 732.12 ; found, 733.7.




Figure 9S. $^1\text{H-NMR}$ spectrum of 1,5-dioctadecyl *N*-histidyl-L-glutamate (**2c**).

1,5-Dioctadecyl *N*-histidyl-L-glutamate (2c): R_f 0.13 (CHCl_3 :MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 60H, $\text{CH}_2(\text{stearyl})$), 1.52-1.63 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 1.94-2.22 (m, 2H, NHCHCH_2), 2.37 (t, 2H, $\text{NHCHCH}_2\text{CH}_2$), 2.85-3.18 (q, 2H, NH_2CHCH_2), 4.05-4.13 (m, 4H, COOCH_2), 4.52 (q, 1H, NH_2CH), 6.88 (d, 1H, $\text{CH}_2\text{C}=\text{CH}$), 7.50 (d, 1H, $\text{N}=\text{CH}$). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{47}\text{H}_{88}\text{N}_4\text{O}_5$, 789.23; found, 789.7.




Figure 10S. $^1\text{H-NMR}$ spectrum of 1,5-ditetradecyl *N*-arginyl-L-glutamate (**3a**).

1,5-Ditetradecyl *N*-arginyl-L-glutamate (3a): R_f 0.24 (CHCl_3 :MeOH 4:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 10:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.27 (m, 44H, CH_2 (myristoyl)), 1.61 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 1.72 (m, 2H, $\text{NH}_2\text{CHCH}_2\text{CH}_2$), 1.78-1.92 (m, 2H, NH_2CHCH_2), 1.96-2.25 (m, 2H, NHCHCH_2), 2.42 (t, 2H, $\text{NHCHCH}_2\text{CH}_2$), 3.18 (m, 2H, $\text{CH}_2\text{NHC}=\text{N}$), 4.06-4.14 (m, 4H, COOCH_2), 4.51 (q, 1H, CONHCH). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{39}\text{H}_{77}\text{N}_5\text{O}_5$, 696.06; found, 696.7.




Figure 11S. $^1\text{H-NMR}$ spectrum of 1,5-dihexadecyl *N*-arginyl-L-glutamate (**3b**).

1,5-Dihexadecyl *N*-arginyl-L-glutamate (3b**):** R_f 0.07 (CHCl_3 :MeOH 10:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 4:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 52H, CH_2 (palmitoyl)), 1.61 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 1.72 (m, 2H, $\text{NH}_2\text{CHCH}_2\text{CH}_2$), 1.86-2.02 (m, 2H, NHCHCH_2), 1.94-2.26 (m, 2H, NHCHCH_2), 2.43 (t, 2H, $\text{NHCHCH}_2\text{CH}_2$), 3.18 (m, 2H, $\text{CH}_2\text{NHC}=\text{N}$), 3.96 (t, 1H, NH_2CHCH_2), 4.06-4.15 (m, 4H, COOCH_2), 4.51 (q, 1H, NHCHCH_2). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{43}\text{H}_{85}\text{N}_4\text{O}_5$, 752.17; found, 752.8.




Figure 12S. $^1\text{H-NMR}$ spectrum of 1,5-dioctadecyl *N*-arginyl-L-glutamate (**3c**).

1,5-Dioctadecyl *N*-arginyl-L-glutamate (3c): R_f 0.05 (CHCl_3 :MeOH 10:1). $^1\text{H-NMR}$ (CDCl_3 :MeOD 4:1, 500 MHz, δ ppm): 0.88 (t, 6H, CH_2CH_3); 1.26 (m, 60H, $\text{CH}_2(\text{stearyl})$), 1.60 (m, 4H, $\text{COOCH}_2\text{CH}_2$), 1.52, 1.72 (m, 2H, $\text{NH}_2\text{CHCH}_2\text{CH}_2$), 1.88-2.02 (m, 2H, NHCHCH_2), 1.96-2.25 (t, 2H, NHCHCH_2), 3.19 (m, 2H, $\text{CH}_2\text{NHC}=\text{N}$), 4.00 (t, 1H, NHCHCH_2), 4.05-4.16 (m, 4H, COOCH_2), 4.51 (q, 1H, NH_2CH). MS(ESI): $(\text{M}+\text{H})^+$ calcd. for $\text{C}_{39}\text{H}_{77}\text{N}_5\text{O}_5$, 808.27; found, 808.8.